GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | H2ax | increases expression | EXP | | 6480464 | CTD | Camptothecin results in increased expression of H2AX protein | PMID:17875725 | H2ax | increases expression | ISO | H2AX (Homo sapiens) | 6480464 | CTD | Camptothecin results in increased expression of H2AX protein; Camptothecin results in increased expression of H2AX protein modified form | PMID:21227924 PMID:22302033 PMID:25269479 PMID:25772433 PMID:30720231 | H2ax | increases expression | ISO | H2ax (Mus musculus) | 6480464 | CTD | Camptothecin results in increased expression of H2AX protein | PMID:17875725 | H2ax | increases phosphorylation | ISO | H2AX (Homo sapiens) | 6480464 | CTD | Camptothecin results in increased phosphorylation of H2AX protein | PMID:21646468 PMID:32482060 | H2ax | multiple interactions | ISO | H2AX (Homo sapiens) | 6480464 | CTD | 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; [Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; [MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Camptothecin; [Propyl Gallate results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]]; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; PPP2R2A protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein] | PMID:21227924 PMID:21693595 PMID:22302033 PMID:25269479 PMID:25772433 PMID:26928355 PMID:30720231 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |